Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833058 | 1.00 | HRH3 (0.42) | HRH3KDM4EHTTMAP4K4ALDH1A1 | |
| SCHEMBL30833055 | 0.84 | L3MBTL3 (0.43) | HRH3KDM4EHTTALDH1A1GAA | |
| SCHEMBL24620324 | 0.84 | L3MBTL3 (0.43) | HRH3KDM4EHTTALDH1A1GAA | |
| SCHEMBL24620327 | 0.79 | FGFR3 (0.43) | ALDH1A1 | |
| SCHEMBL30833051 | 0.79 | FGFR3 (0.43) | ALDH1A1 | |
| SCHEMBL29791383 | 0.75 | LRRK2 (0.41) | HRH3ATR | |
| SCHEMBL12714783 | 0.74 | ALDH1A1 (0.54) | KDM4EHTTALDH1A1GAA | |
| SCHEMBL24620323 | 0.73 | ALDH1A1 (0.49) | KDM4EHTTALDH1A1GAA | |
| SCHEMBL21245786 | 0.73 | ALDH1A1 (0.50) | KDM4EHTTMAP4K4ALDH1A1GAA | |
| SCHEMBL21267453 | 0.73 | ALDH1A1 (0.50) | KDM4EHTTMAP4K4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | HRH3 3006/4885KDM4E 1801/4885HTT 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.